Ramesh Rengan, MD, PhD

Dr. Ramesh Rengan MD, PhD
faculty member

Ramesh Rengan, MD, PhD

Senior Vice President and Director
Radiation Oncology Division, Fred Hutch

Clinical Research Division, Fred Hutch

Fax: 206.417.0347
Mail Stop: D3-100

Dr. Ramesh Rengan studies photon- and proton-based radiation treatment for cancer. His main objective is to improve the therapeutic benefit and minimize the harms of these forms of radiation. He is interested in how radiation therapy can synergize with immune-harnessing cancer treatments called immunotherapies. To this end, he is learning how to use radiation to trigger an anti-cancer immune response to treat patients with advanced lung cancer, melanoma, lymphoma, kidney cancer and other malignancies. He also develops new methods to visualize and measure the effects of radiation therapy on cancerous and healthy tissues. Finally, he studies health care disparities and ways to increase patient access to radiation therapy. Dr. Rengan treats patients with a variety of solid-tumor cancers.

Other Appointments & Affiliations

Professor, Department of Radiation Oncology
University of Washington School of Medicine

Chair, Department of Radiation Oncology
UW Medicine

Peter Wootton Professorship in Radiation Oncology
UW Medicine


Residency, Radiation Oncology, Memorial Sloan-Kettering Cancer Center, 2006

MD, University of Michigan, 2001

PhD, Biological Chemistry, University of Michigan, 2001

MSc, Biological Chemistry, University of Michigan, 1995

BSc, Chemistry, University of Michigan, 1992

Research Interests

Approaches to improve the therapeutic ratio in solid tumors to ionizing photon or proton radiation

Pre-clinical and clinical strategies to utilize radiation to trigger an anti-tumor immune response in patients with advanced malignancies

Healthcare disparities and expanded access to radiation treatment in low-resource environments

Photon- and Proton based radiation regimens to trigger an immune response to augment immunotherapeutic platforms in solid malignancies including NSCLC, melanoma, lymphoma, and renal cell carcinoma

Development of biomarkers of immunologic and tumor response to ionizing radiation in solid tumors

Functional imaging to interrogate tumor and normal tissue response to ionizing radiation in solid tumors

Impact of healthcare resources on radiation-related outcome in solid tumors

Find a Clinical Trial

For the Media

The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.

Email media@fredhutch.org or call 206.667.2210